JP
John P. Pitman

Well Cited

43
Works
388
Citations
10
H-Index
Search Authors
Author Statistics
External Links
OpenAlex Profile ORCID Profile

John P. Pitman

Also known as: J. P. Pitman, J. Pitman, John P Pitman, John P. Pitman, John Pitman

43

Total Works

388

Citations

10

H-Index

12

i10-Index

Citation & Works Trend by Year
18 years active
Top Research Topics
Blood transfusion and management (31) Blood donation and transfusion practices (30) Blood groups and transfusion (11) HIV/AIDS Research and Interventions (9) Trauma, Hemostasis, Coagulopathy, Resuscitation (6)
Recent Publications
15 shown
Year Publication Title Citations Action
2026 Prospective multi‐centre haemovigilance of amotosalen and ultraviolet A ‐treated platelets and plasma in routine clinical use Vox Sanguinis 0
2026 A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)—protocol for a phase 3 clinical trial Trials 0
2026 A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)—protocol for a phase 3 clinical trial Figshare 0
2026 Additional file 1 of A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)—protocol for a phase 3 clinical trial Figshare 0
2025 A Randomized, Double-Blind, Controlled, Parallel Group Study with Amustaline/Glutathione Pathogen Reduced Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study): -- Protocol for a Phase 3, Randomized, Controlled Trial Research Square 0
2025 A novel acridine flow cytometry marker to track post‐transfusion amustaline/glutathione pathogen‐reduced red blood cell survival in sickle cell disease patients Transfusion 5
2024 Tracking Entire Units of Transfused Pathogen-Reduced Red Cells in Sickle Cell Patients Using a Novel Acridine Marker Blood 0
2024 Introduction of 7‐day amotosalen/ ultraviolet A light pathogen‐reduced platelets in Honduras: Impact on platelet availability in a lower middle‐income country Vox Sanguinis 2
2023 Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial Trials 14
2023 P‐TS‐25 | Developing a Tool to Assess Red Blood Cell Clearance in Vivo Utilizing Pathogen‐Reduced RBCs Transfusion 2
2023 P‐TS‐24 | Design of ReCePI, a Randomized, Double‐Blinded, Phase III Study to Evaluate the Efficacy and Safety of Pathogen Reduced RBCs in Complex Cardiac Surgery Transfusion 0
2023 Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7‐day storage Transfusion 11
2022 P-21 EIR de grade 3 associés à la transfusion de plaquettes Transfusion Clinique et Biologique 0
2021 Sécurité des plaquettes amotosalen/UVA en France sur 10 ans Transfusion Clinique et Biologique 0
2019 Progress towards an appropriate pathogen reduction technology for whole blood in Africa ISBT Science Series 10

Data source: OpenAlex API